Risk management of biosimilars in oncology: each medicine is a work in progress

Abstract

Drug licensing and drug safety monitoring for standard chemical entities have been established and are routinely used. These have resulted in a solid foundation of knowledge from which confident therapeutic decisions can be made. For many chemical entities, this advanced level of experience is also present for the generic products. The expertise surrounding… (More)
DOI: 10.1007/s11523-011-0188-3

Topics

  • Presentations referencing similar topics